COVID-19 VACCINE DEVELOPMENT
AdaptVac, as part of the EU H2020 funded PREVENT-nCoV consortium, is focused on developing a SARS-CoV-2 (COVID-19) vaccine using our capsid Virus-Like Particle (VLP) display technology.
VIRUS-LIKE PARTICLE DISPLAY TECHNOLOGY
Virus-like particles (VLPs) represent a significant advance in the development of subunit vaccines, combining high safety and efficacy. Their particulate nature and dense repetitive subunit organisation makes them ideal scaffolds for display of vaccine antigens. Traditional approaches for VLP-based antigen display require labor-intensive trial-and-error optimisation, and often fail to generate dense antigen display. Here we utilise the split-protein conjugation system to generate stable isopeptide bound antigen-VLP complexes by simply mixing of the antigen and VLP components.
COLLABORATIONS
AdaptVac has an open approach to our VLP display technology and welcomes collaborations with leading research groups and companies to advance innovative vaccines and immunotherapies.
GET IN TOUCH
Agern Alle 1
Hørsholm, 2970
Denmark
CVR number: 38732730
+45 26394649